Difference between revisions of "Part:BBa K404118"
(5 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K404118 short</partinfo> | <partinfo>BBa_K404118 short</partinfo> | ||
+ | |||
+ | {| style="color:black" cellpadding="6" cellspacing="1" border="2" align="right" | ||
+ | ! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404118 [AAV2]-left-ITR_pCMV_betaglobin] | ||
+ | |- | ||
+ | ! colspan="2"|[[Image:Freiburg10_Vectorplasmid precursors 5.png|200px]] | ||
+ | |- | ||
+ | |'''BioBrick Nr.''' | ||
+ | |[https://parts.igem.org/Part:BBa_K404118 BBa_K404118] | ||
+ | |- | ||
+ | |'''RFC standard''' | ||
+ | |[https://parts.igem.org/Help:Assembly_standard_10 RFC 10] | ||
+ | |- | ||
+ | |'''Requirement''' | ||
+ | |pSB1C3<br> | ||
+ | |- | ||
+ | |'''Source''' | ||
+ | |pAAV_MCS provided by Stratagene | ||
+ | |- | ||
+ | |'''Submitted by''' | ||
+ | |[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] | ||
+ | |} | ||
+ | <br /> | ||
+ | <p style="text-align:justify;"> | ||
+ | |||
+ | [[Image:Freiburg10_Vectorplasmid precursors 5.png|left|thumb|300px]] | ||
<br/> | <br/> | ||
+ | <br/> | ||
+ | <br/> | ||
+ | <br/><br/><br/><br/><br/><br/><br/><br/><br/><br/> | ||
− | + | <html> | |
+ | <head> | ||
+ | <meta http-equiv="Content-Type" | ||
+ | content="text/html; charset=windows-1252"> | ||
+ | <meta name="Generator" | ||
+ | content="Microsoft Word 14 (filtered)"> | ||
+ | <style> | ||
+ | <!-- | ||
+ | /* Font Definitions */ | ||
+ | @font-face | ||
+ | {font-family:Cambria; | ||
+ | panose-1:2 4 5 3 5 4 6 3 2 4;} | ||
+ | @font-face | ||
+ | {font-family:Calibri; | ||
+ | panose-1:2 15 5 2 2 2 4 3 2 4;} | ||
+ | /* Style Definitions */ | ||
+ | p.MsoNormal, li.MsoNormal, div.MsoNormal | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:0cm; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | h1 | ||
+ | {mso-style-link:"Heading 1 Char"; | ||
+ | margin-top:24.0pt; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:0cm; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | page-break-after:avoid; | ||
+ | font-size:14.0pt; | ||
+ | font-family:"Cambria","serif"; | ||
+ | color:red;} | ||
+ | p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | span.Heading1Char | ||
+ | {mso-style-name:"Heading 1 Char"; | ||
+ | mso-style-link:"Heading 1"; | ||
+ | font-family:"Cambria","serif"; | ||
+ | color:red; | ||
+ | font-weight:bold;} | ||
+ | .MsoChpDefault | ||
+ | {font-family:"Calibri","sans-serif";} | ||
+ | .MsoPapDefault | ||
+ | {margin-bottom:10.0pt; | ||
+ | line-height:115%;} | ||
+ | @page WordSection1 | ||
+ | {size:612.0pt 792.0pt; | ||
+ | margin:70.85pt 70.85pt 2.0cm 70.85pt;} | ||
+ | div.WordSection1 | ||
+ | {page:WordSection1;} | ||
+ | --> | ||
+ | </style> | ||
+ | </head> | ||
+ | <body lang="EN-US"> | ||
+ | <div class="WordSection1"> | ||
+ | <h1><span style="color: windowtext;">[AAV2]-left-ITR_phTERT_betaglobin</span></h1> | ||
+ | <p class="MsoNormal"> </p> | ||
+ | <p class="MsoNormal"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Producing | ||
+ | recombinant virus particles for therapeutical applications is, besides | ||
+ | specific | ||
+ | cell targeting, purification and quantification assays of AAV-2, one | ||
+ | intention | ||
+ | of the Virus Construction Kit provided by the iGEM team | ||
+ | Freiburg_Bioware 2010. | ||
+ | For obtaining a modular toolkit, the complex biological system of the | ||
+ | Adeno-associated virus serotype 2 was examined by an exhaustive | ||
+ | literature | ||
+ | search. Subsequently, the essential components for AAV-2 particle | ||
+ | production | ||
+ | were extracted and redesigned to match the iGEM standard.</span></p> | ||
+ | <p class="MsoNormal"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">The provided | ||
+ | tripartite system is independent of a superinfection | ||
+ | of Adeno- or herpes | ||
+ | simplex viruses since the genes encoding the required helper-proteins | ||
+ | are | ||
+ | co-transfected. Inside the eukaryotic host cell, the DNA sequence | ||
+ | containing | ||
+ | the inverted terminal repeats (ITRs) is extracted and later | ||
+ | encapsidated into | ||
+ | the preformed capsids after production of single-stranded DNA. | ||
+ | Consequently, | ||
+ | this plasmid is known as the vector plasmid (pGOI). Promoter, <i>beta-globin</i> | ||
+ | intron and the hGH terminator signal are flanked by the ITRs (ITRs, | ||
+ | BBa_K404100 | ||
+ | and BBa_K404101) and regulate transgene expression. The vector plasmid | ||
+ | containing the desired gene of interest is cotransfected with the | ||
+ | RepCap | ||
+ | plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper | ||
+ | plasmid. </span></p> | ||
+ | <p class="MsoNormal"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Several | ||
+ | assembly steps have to be performed in order to obtain the fully | ||
+ | assembled vector | ||
+ | plasmid ensuring a layer of specificity by using a tumor-specific | ||
+ | promoter | ||
+ | phTERT (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404106)</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">. | ||
+ | Facilitating the cloning steps the | ||
+ | iGEM team Freiburg_Bioware 2010 provide the 5´nucleotide components in | ||
+ | respect | ||
+ | to the desired gene of interest which are the left inverted terminal | ||
+ | repeat (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404100</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">) followed by | ||
+ | the phTERT promoter (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404106) and | ||
+ | a putative | ||
+ | enhancer-element (BBa_K404107). </span></p> | ||
+ | <p class="MsoNormal"> </p> | ||
+ | </div> | ||
+ | </body> | ||
+ | </html> | ||
+ | |||
+ | <br><br><br><br><br> | ||
Line 9: | Line 189: | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | |||
<!-- --> | <!-- --> |
Latest revision as of 12:31, 31 October 2010
[AAV2]-left-ITR_phTERT_betaglobin
[AAV2-left-ITR_pCMV_betaglobin] | |
---|---|
BioBrick Nr. | BBa_K404118 |
RFC standard | RFC 10 |
Requirement | pSB1C3 |
Source | pAAV_MCS provided by Stratagene |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
[AAV2]-left-ITR_phTERT_betaglobin
Producing recombinant virus particles for therapeutical applications is, besides specific cell targeting, purification and quantification assays of AAV-2, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex biological system of the Adeno-associated virus serotype 2 was examined by an exhaustive literature search. Subsequently, the essential components for AAV-2 particle production were extracted and redesigned to match the iGEM standard.
The provided tripartite system is independent of a superinfection of Adeno- or herpes simplex viruses since the genes encoding the required helper-proteins are co-transfected. Inside the eukaryotic host cell, the DNA sequence containing the inverted terminal repeats (ITRs) is extracted and later encapsidated into the preformed capsids after production of single-stranded DNA. Consequently, this plasmid is known as the vector plasmid (pGOI). Promoter, beta-globin intron and the hGH terminator signal are flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate transgene expression. The vector plasmid containing the desired gene of interest is cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper plasmid.
Several assembly steps have to be performed in order to obtain the fully assembled vector plasmid ensuring a layer of specificity by using a tumor-specific promoter phTERT (BBa_K404106). Facilitating the cloning steps the iGEM team Freiburg_Bioware 2010 provide the 5´nucleotide components in respect to the desired gene of interest which are the left inverted terminal repeat (BBa_K404100) followed by the phTERT promoter (BBa_K404106) and a putative enhancer-element (BBa_K404107).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]